Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
V127916-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $53.90 | |
V127916-10mg | 10mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $75.90 | |
V127916-50mg | 50mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $118.90 |
Synonyms | Lumacaftor|936727-05-8|VX-809|VX809|VX 809|3-(6-(1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid|VRT-826809|VRT 826809|VX-809 (Lumacaftor)|EGP8L81APK|3-(6-{[1-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-cyclopro |
---|---|
Specifications & Purity | ≥98% |
Storage Temp | Store at -20°C |
Shipped In | Dry ice |
Grade | Moligand™ |
Action Type | STABILISER |
Mechanism of action | Cystic fibrosis transmembrane conductance regulator stabiliser |
Product Description | VX-809 (Lumacaftor) acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM. |
ALogP | 4.4 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic acid |
---|---|
INCHI | InChI=1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31) |
InChi Key | UFSKUSARDNFIRC-UHFFFAOYSA-N |
Canonical SMILES | CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O |
Isomeric SMILES | CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O |
PubChem CID | 16678941 |
Molecular Weight | 452.41 |
PubChem CID | 16678941 |
---|---|
CAS Registry No. | 936727-05-8 |
ChEMBL Ligand | CHEMBL2103870 |
Wikipedia | Lumacaftor |
PEP | lumacaftor |
DrugCentral Ligand | 5010 |
RCSB PDB Ligand | VX8 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
F1524095 | Certificate of Analysis | Jan 24, 2023 | V127916 |
Solubility | DMSO 91 mg/mL Water <1 mg/mL Ethanol 6 mg/mL |
---|
Pictogram(s) | GHS06, GHS08, GHS05, GHS07 |
---|---|
Signal | Danger |
Hazard Statements | H301:Toxic if swallowed H318:Causes serious eye damage H312:Harmful in contact with skin H372:Causes damage to organs through prolonged or repeated exposure H360:May damage fertility or the unborn child |
Precautionary Statements | P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P260:Do not breathe dust/fume/gas/mist/vapors/spray. P270:Do not eat, drink or smoke when using this product. P362+P364:Take off contaminated clothing and wash it before reuse. P330:Rinse mouth. P203:Obtain, read and follow all safety instructions before use. P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes. P301+P316:IF SWALLOWED: Get emergency medical help immediately. P305+P354+P338:IF IN EYES: Immediately rinse with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. P318:if exposed or concerned, get medical advice. P317:Get emergency medical help. P319:Get medical help if you feel unwell. |
1. Okiyoneda T, Veit G, Dekkers JF, Bagdany M, Soya N, Xu H, Roldan A, Verkman AS, Kurth M, Simon A et al.. (2013) Mechanism-based corrector combination restores ΔF508-CFTR folding and function.. Nat Chem Biol, 9 (7): (444-54). [PMID:23666117] |
2. Ren HY, Grove DE, De La Rosa O, Houck SA, Sopha P, Van Goor F, Hoffman BJ, Cyr DM. (2013) VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1.. Mol Biol Cell, 24 (19): (3016-24). [PMID:23924900] |
3. Fiedorczuk K, Chen J. (2022) Mechanism of CFTR correction by type I folding correctors.. Cell, 185 (1): (158-168.e11). [PMID:34995514] |